about
P3781
IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice.Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.Irinotecan (CPT-11)-induced elevation of bile acids potentiates suppression of IL-10 expression.A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)Development and characterization of pH responsive polymeric nanoparticles of SN-38 for colon cancer.Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.Long-term survival in small-cell carcinoma of the endometrium with liver and brain metastases.P7 peptides targeting bFGF sensitize colorectal cancer cells to CPT-11.Biophysical and molecular docking insight into interaction mechanism and thermal stability of human serum albumin isoforms with a semi-synthetic water-soluble camptothecin analog irinotecan hydrochloride.[Pharmacokinetics and tissue distribution of irinotecan hydrochloride nanoparticles].[Pharmacokinetics of SN-38 in rats and tissue distribution of 7-ethyl-10-hydroxycamptothecin in mice after intravenous injection of irinotecan hydrochloride nanoparticles][Clinical efficacy of low-dose CDDP and CPT-11 therapy as second- or third-line chemotherapy for advanced and recurrent gastric cancer]Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosisLangmuir monolayers and Differential Scanning Calorimetry for the study of the interactions between camptothecin drugs and biomembrane models
P921
Q33830896-68537672-5F98-4264-8945-8A970073052BQ35829622-1AE18831-6082-4394-B143-EBB973B40F1FQ36479746-E2A945E1-D7FB-4D4E-BCEF-136000630F3FQ37724509-44F81913-FCAE-45B3-8BE6-5AB081E0048BQ38821844-6FE2177A-C4F4-4555-B91E-68A83DB4C120Q38902330-ED74D3BE-635E-4F91-B660-2154AD62DB83Q40559800-42A28C32-22A7-4FE3-B38D-687108A76F26Q43433911-DBA3CABE-931D-4995-891A-1C5B5E6ABA32Q46548051-65D67491-AAF0-4CD4-98A1-A28B42B7EEF8Q46697345-E3C7D6FE-4BB1-484B-A923-CCADB2FC175DQ85333729-650D1DA9-872D-4098-8699-F68177180EF4Q85365073-8963B189-7AEA-4F9C-92C3-7F2BF5E7238BQ86617754-FC52D3B0-1676-4FE9-922C-7816F964BCA2Q86888092-6DEC9FF6-8F08-4245-96C6-052DFC83ED5D
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
irinotecan hydrochloride trihydrate
@en
type
label
irinotecan hydrochloride trihydrate
@en
altLabel
CPT 11
@en
CPT-11
@en
Irinotecan hydrochloride hydrate
@en
U-101,440E
@en
irinotecan hydrochloride trihydrate
@en
irinotecan monohydrochloride trihydrate
@en
prefLabel
irinotecan hydrochloride trihydrate
@en
P661
P662
P665
P683
P1579
P2017
CCC1=C2C=C(C=CC2=NC3=C1CN4C3=C ...... =O)N6CCC(CC6)N7CCCCC7.O.O.O.Cl
P2067
P2115
N0000148442
P231
136572-09-3
P232
P233
CCC1=C2C=C(C=CC2=NC3=C1CN4C3=CC5=C(C4=O)COC(=O)C5(CC)O)OC(=O)N6CCC(CC6)N7CCCCC7.O.O.O.Cl
P234
1S/C33H38N4O6.ClH.3H2O/c1-3-22 ...... H3;1H;3*1H2/t33-;;;;/m0..../s1
P235
KLEAIHJJLUAXIQ-JDRGBKBRSA-N
P2566
100.118.373
P274
C₃₃H₄₅ClN₄O₉
P2840
P2892
P3117
DTXSID60929485